nicabate clear patch nicotine 7mg/24 hours transdermal drug delivery system sachet
haleon australia pty ltd - nicotine, quantity: 36 mg (equivalent: nicotine, qty 7 mg/24 h) - drug delivery system, transdermal - excipient ingredients: ethylene dioleamide; polyisobutylene; ethylene/vinyl acetate copolymer; polyethylene; titanium dioxide; ethyl acetate; ethanol; isopropyl alcohol; methoxyisopropanol; ethylcellulose; pyroxylin - for the treatment of nicotine dependence as an aid to smoking cessation.
fentanyl sandoz fentanyl 37 micrograms/hour transdermal drug delivery system sachet
sandoz pty ltd - fentanyl, quantity: 6.3 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.
dutran 100 fentanyl 100 mcg/hr transdermal patch pouch
medis pharma pty ltd - fentanyl, quantity: 16.5 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.
dutran 75 fentanyl 75 mcg/hr transdermal patch pouch
medis pharma pty ltd - fentanyl, quantity: 12.375 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.
durogesic dtrans 25micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 25microgram/1hour
durogesic dtrans 50micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 50microgram/1hour
durogesic dtrans 75micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 75microgram/1hour
durogesic dtrans 100micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 100microgram/1hour
durogesic dtrans 12micrograms/hour transdermal patches
janssen-cilag ltd - fentanyl - transdermal patch - 12microgram/1hour
matrifen 12micrograms/hour transdermal patches
teva uk ltd - fentanyl - transdermal patch - 12microgram/1hour